Elderly patients with dementia-related psychosis who are treated with atypical antipsychotic drugs are at an increased risk of death and cerebrovascular-related adverse events, including stroke. Prolongs QT interval and may be associated with arrhythmia and sudden death. Neuroleptic malignant syndrome (immediate discontinuation), tardive dyskinesia, hyperglycemia and diabetes mellitus, seizure, and orthostatic hypotension (dizziness, tachycardia, and syncope) can occur. Leukopenia, neutropenia, and agranulocytosis have been reported with antipsychotics (should be discontinued at the first sign of a decline in WBC in the absence of other causative factors). Suicide, priapism, sedation, impaired core body temperature regulation, weight gain, and potential for cognitive and motor impairment have also been observed. May cause anticholinergic effects (confusion, agitation, constipation, xerostomia, blurred vision, urinary retention). Antipsychotic use has been associated with esophageal dysmotility and aspiration. Extrapyramidal symptoms (EPS) including pseudoparkinsonism, acute dystonic reactions, akathisia, and tardive dyskinesia (risk of these reactions is generally much lower relative to typical/conventional antipsychotics) may occur. Risk of dystonia (and probably other EPS) may be greater with increased doses, use of conventional antipsychotics, males, and younger patients.